Production and characterization of $^{111}Ag$ radioisotope for medical use in a TRIGA Mark II Nuclear Reactor.

Morselli L., Lunardon M., Stevanato L., Andrighetto A., Corradetti S., Donzella A., Zenoni A., Asti M., Bortolussi S., Zangrando L., Salvini A., Gandini A., Ferrari M.
  Venerdì 16/09   09:00 - 13:30   Aula E - Rosalind Franklin   V - Biofisica e fisica medica   Presentazione
RadioPharmaceutical Therapy (RPT) comes forth as a promising technique to treat a wide range of tumors while ensuring low collateral damage to nearby healthy tissues. Recently $^{111}Ag$ was proposed as a promising core of a therapeutic radiopharmaceutical for the treatment of large tumors given its penetrating $\beta$-emission. Moreover, it also emits two $\gamma$-rays ({342 ${keV} I_{\gamma}=6.7%$ and $245 {keV} I_{\gamma}=1.24%$), suitable for SPECT imaging, making the therapy follow-up feasible. Finally, its half-life of $7.5 {days}$ allows for all the mandatory radiochemical procedures that lead from the radioisotopes to the actual radiopharmaceutical. In this contribution, the production of $^{111}Ag$ via neutron activation inside a nuclear reactor was modeled using two different Monte Carlo codes (MCNPX and PHITS) and compared with experimental measurements. The whole process was simulated starting from an MCNPX-based reactor model. Irradiation experiments were carried out using both natural and enriched palladium samples, irradiated inside the central thimble of a Triga Mark II Research Reactor. A natural palladium sample was measured also after the chemical separation procedure.